NEUP — Neuphoria Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1191070 ·
Last close
$3.65
Market Cap
$19.73M
52W High
$21.40
52W Low
$3.19
ADV30
36,869
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,174,165 | — | -183,921 | -4,904,456 | 28,709,016 | 19,865,531 | 4,108,994 |
| Mar 2026 | 0 | — | -827,284 | -505,063 | 34,809,200 | 19,440,655 | 5,385,256 |
| Dec 2025 | 0 | — | -2,345,682 | 1,864,092 | 36,598,302 | 22,170,414 | 6,897,478 |
| Sep 2025 | 0 | — | -5,652,689 | -9,906,504 | 27,343,913 | 13,649,638 | 14,833,726 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,113,476
Investing CF
—
Financing CF
$19,078,384
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.28
As of
2026-09-20
Balance + Analyst (yfinance extras)
Retained Earnings
$-186,894,178
Inventory
—
Receivables
$1,605,340
ST Investments
—
EBIT TTM
$3,146,311
Pretax Income TTM
$2,529,120
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,174,165
EBITDA
$-8,346,621
Free Cash Flow
$-8,339,007
Enterprise Value
$190,749
Total Cash
$19,865,532
Total Debt
$34,345
Shares Out
5,404,551
Trailing EPS
$-7.90
Book Value
$5.47
ROE
-61.7%
ROA
-19.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,174,165 | -9,009,576 | -13,451,931 | 28,709,016 | 4,108,994 | 24,600,022 | -12,353,074 |
| Jun 2025 | — | — | — | — | — | — | — |
| Jun 2024 | 0 | -17,797,161 | -15,492,166 | 27,649,093 | 10,158,721 | 17,490,372 | -14,680,777 |
| Jun 2023 | 0 | -21,560,234 | -21,381,677 | 28,562,948 | 6,552,385 | 22,010,563 | -14,637,720 |
| Jun 2022 | 181,356 | -14,681,036 | -14,968,465 | 44,927,475 | 5,776,593 | 39,150,882 | -14,965,802 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATOS | ATOSSA THERAPEUTICS, INC. | $19.56M | $1.96 | — |
| MCUJF | MEDICURE INC | $20.35M | $1.95 | — |
| AKTX | Akari Therapeutics Plc | $19.10M | $9.81 | — |
| MRKR | Marker Therapeutics, Inc. | $18.76M | $1.12 | — |
| PBM | PSYENCE BIOMEDICAL LTD. | $21.61M | $5.66 | — |
News headlines (Yahoo Finance, 1h cache)
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
2026-09-24 05:00 · Yahoo
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell
2026-07-23 14:15 · Yahoo
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
2026-06-26 20:15 · Yahoo
Scancell confirms advanced talks over reverse merger with Neuphoria
2026-06-26 13:45 · Yahoo
Scancell sees high demand in retail share offer, seals £15.7m from UK investors
2026-07-27 11:41 · Yahoo
SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612
2026-07-24 13:00 · Yahoo
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
2026-07-23 10:11 · Yahoo
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership
2026-07-01 22:01 · Yahoo
Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation
2026-02-19 11:00 · Yahoo
Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees
2025-12-08 22:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.